On July 11, the Senate voted to approve legislation that will limit the ability of pharmaceutical companies’ patent thickets to slow biosimilar competition. The outlook for this legislation, called the Affordable Prescriptions for Patients Act (Senate Bill 150), is by no means assured. Patent thickets have been a bane of biosimilar manufacturers from the implementation … Continue reading Bill to Limit Patent Thickets Passes Senate, Goes to House